tert-Butyl Hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate - CAS 141449-85-6
Catalog: |
BB062086 |
Product Name: |
tert-Butyl Hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate |
CAS: |
141449-85-6 |
Synonyms: |
tert-butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate; 2-Boc-Hexahydro-pyrrolo[3,4-C]pyrrole; 2-BOC-Hexahydropyrrolo[3,4-c]pyrrole; tert-butyl octahydropyrrolo[3,4-c]pyrrole-2-carboxylate; 2-BOC-HEXAHYDRO-PYRRPOL[3,4-C]PYRROLE; tert-butyl 2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole-5-carboxylate; Hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid tert-butyl ester |
IUPAC Name: | tert-butyl 2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole-5-carboxylate |
Description: | tert-Butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (cas# 141449-85-6) is a useful research chemical. |
Molecular Weight: | 212.28 |
Molecular Formula: | C11H20N2O2 |
Canonical SMILES: | CC(C)(C)OC(=O)N1CC2CNCC2C1 |
InChI: | InChI=1S/C11H20N2O2/c1-11(2,3)15-10(14)13-6-8-4-12-5-9(8)7-13/h8-9,12H,4-7H2,1-3H3 |
InChI Key: | FYUVLZRRIRGSTE-UHFFFAOYSA-N |
GHS Hazard Statement: | H302 (66.67%): Harmful if swallowed [Warning Acute toxicity, oral] |
Precautionary Statement: | P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
EP-3945091-A1 | Novel vdac1 inhibitors | 20200731 |
CN-113999233-A | BTK inhibitor ring derivative, preparation method and pharmaceutical application thereof | 20200728 |
WO-2022019597-A1 | Compound for androgen receptor degradation, and pharmaceutical use thereof | 20200721 |
WO-2021242753-A1 | Mitochondrial targeting compounds for the treatment of associated diseases | 20200526 |
WO-2021228223-A1 | Deuterated akt kinase inhibitor | 20200515 |
CN-113521299-A | Pyrazolopyrimidine derivative or conjugate thereof, preparation method and application thereof | 20200415 |
WO-2021105474-A1 | New compounds for treatment of diseases related to dux4 expression | 20191129 |
WO-2021105481-A1 | Novel compounds for treatment of diseases related to dux4 expression | 20191129 |
WO-2021066088-A1 | Novel triazine derivative | 20191002 |
CN-112574235-A | RET inhibitor, pharmaceutical composition and application thereof | 20190929 |
Complexity: | 248 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 212.152477885 |
Formal Charge: | 0 |
Heavy Atom Count: | 15 |
Hydrogen Bond Acceptor Count: | 3 |
Hydrogen Bond Donor Count: | 1 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 212.152477885 |
Rotatable Bond Count: | 2 |
Topological Polar Surface Area: | 41.6Ų |
Undefined Atom Stereocenter Count: | 2 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 0.7 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Other Building Blocks
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS